Hyperprogression after anti-programmed death-1 therapy in a patient with urothelial bladder carcinoma: A case report

Figure 2 Some subcutaneous nodules and intrapelvic metastases increased significantly, indicating that the patient possibly experienced hyperprogression after immunotherapy. A: Subcutaneous nodules and intrapelvic nodules two weeks before starting immunotherapy (baseline); B: After 2 cycles of immunological checkpoint inhibitor treatment, abdominal subcutaneous metastases and intrapelvic metastases were significantly increased; C: After 2 wk of pemetrexed chemotherapy, the subcutaneous metastases of the abdominal wall, gluteus maximus metastases, and the intrapelvic metastases did not increase significantly.